Since it is now appreciated that CD8+ T cells play a disproportionately important role in the immunosurveillance and elimination of cancers [39], our results suggest that pharmacologic inhibition of HPK1 may preferentially augment memory CD8+ T cell responses and invigorate anti-tumor T cells. Here, CD8A is linked to cancer.